Cargando…
Clinical and Mechanistic Characteristics of Current JAK Inhibitors in IBD
Crohn’s disease (CD) and ulcerative colitis (UC) are chronic, immune-mediated diseases of the gastrointestinal (GI) tract. Their etiology is complex and involves immune (eg, cytokines) and nonimmune (eg, environment) mediated contributions, causing inflammatory damage to the GI tract. Though cytokin...
Autores principales: | Pippis, Elleni J, Yacyshyn, Bruce R |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8522789/ https://www.ncbi.nlm.nih.gov/pubmed/33295611 http://dx.doi.org/10.1093/ibd/izaa318 |
Ejemplares similares
-
Efficacy, Safety and Future Perspectives of JAK Inhibitors in the IBD Treatment
por: Dudek, Patrycja, et al.
Publicado: (2021) -
JAK Inhibitors: Back to Small Molecules for the Treatment of IBD
por: Panés, Julian, et al.
Publicado: (2020) -
Characteristics and Outcomes of IBD Patients with COVID-19 on Tofacitinib Therapy in the SECURE-IBD Registry
por: Agrawal, Manasi, et al.
Publicado: (2020) -
Tools for managing IBD in obese patients: Get JAK in the box!
por: Alrammah, Hanan M., et al.
Publicado: (2021) -
The clinical dilemma of JAK inhibitor failure in myelofibrosis: Predictive characteristics and outcomes
por: Mascarenhas, John O., et al.
Publicado: (2022)